We are continuously evaluating innovative ways to overcome diseases.

Phase 1
Phase 2
Phase 3
DSTAT is in development for acute lung injury in COVID-19 patients. The proposed Phase 2/3 study is a randomized trial designed to determine the safety and efficacy of DSTAT in adults with severe COVID-19 who are at high risk of respiratory failure. Read more here.
DSTAT is in development for the first-line treatment of AML. DSTAT has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration for the treatment of AML. Read more here.
Brincidofovir is being developed for the treatment of smallpox under the FDA’s Animal Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans. Read more here.